Nektar Therapeutics (NKTR)
Develops experimental immunotherapy drugs to treat cancer and autoimmune diseases.
$70.77-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+208.2%
The outlook
Nektar Therapeutics trades near the midpoint of its 52-week range, with the price sitting above both its 50- and 200-day moving averages. Analyst consensus is strongly bullish, with an average price target implying significant upside relative to the current level. The stock's technical position and analyst sentiment both lean constructive.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range57% of the way from its 52-week low to high
Price targetAvg target +117% vs current price
Analyst price target
~12-month · 9 analysts$153.22average target+116.5% vs now
Now $70.77
Low $80.00High $192.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.39B
52-wk high
$109.00
52-wk low
$21.02
50-day avg
$65.73
200-day avg
$62.73
Trailing P/E
—